Competencies by care stage
Dosing
The medicine session itself, covering administration, dose decisions, and the physical setting.
267 competencies mapped to this stage.
Looking for something specific? Ask Blossom
Informed consent, decisional capacity, autonomy, and withdrawal rights
Teaches how to obtain and maintain valid informed consent through clear disclosure, comprehension checks, capacity support, voluntariness, non-coercion, and respect for refusal or withdrawal. The competency also covers consent for screening procedures, recordings, collateral contact, rescue interventions, and documentation of the consent process.
4 roles · 59 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreConfidentiality, privacy, and research data protection
Teaches protection of participant identity, sensitive clinical or occupational information, recordings, and research data. The competency covers coded identifiers, restricted access, secure handling, confidentiality safeguards, and privacy-preserving documentation.
5 roles · 53 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+4 moreScreening, eligibility, and readiness assessment
Teaches how to assess clinical suitability before psychedelic or ketamine treatment, including medical and psychiatric screening, readiness evaluation, contraindication review, inclusion/exclusion criteria, and ongoing eligibility re-checks before dosing.
8 roles · 52 guidelines · 15 courses · 12 providers
5-MeO-DMTDMT / AyahuascaIbogaine+4 moreAcute psychological response and emergency management during dosing
Cluster covering 35 related competencies for monitoring acute psychological effects, recognising and managing distress, crisis containment, emergency escalation, and rescue-medication coordination during psychedelic dosing sessions.
6 roles · 51 guidelines · 2 courses · 2 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreAdverse event identification, documentation, and reporting
Teaches how to detect, elicit, document, and report adverse events and serious adverse events across the participant journey. The focus is accurate source documentation, regulatory reporting discipline, follow-up, and preservation of participant safety and trial integrity.
4 roles · 46 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 morePreparation and integration support
Cluster covering 31 related competencies including: Integration support, Integration therapy, Integration coaching.
7 roles · 43 guidelines · 18 courses · 14 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreSuicide and serious psychiatric risk assessment
Teaches structured assessment of suicidal ideation, intent, psychiatric deterioration, and related high-risk presentations. Learners are trained to use appropriate tools, safety planning, emergency contacts, clinician access, and escalation pathways when risk is identified.
6 roles · 41 guidelines · 1 courses · 1 providers
5-MeO-DMTDMT / AyahuascaKetamine+3 moreManual fidelity, protocol adherence, and deviation management
Teaches faithful delivery of manualized treatment and protocol-defined procedures while documenting and managing unavoidable deviations. The competency protects participant welfare, treatment consistency, data integrity, and sponsor oversight.
5 roles · 39 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaKetamine+4 morePost-dose follow-up, safety monitoring, and retention support
Teaches ongoing participant contact after dosing to support stability, detect delayed adverse effects, maintain therapeutic containment, and sustain adherence to follow-up visits and outcome assessments.
5 roles · 37 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+4 moreDischarge readiness, escort safety, and post-session supervision
Teaches how to determine when a participant is safe to leave after dosing and how to arrange appropriate supervision afterward. The competency covers psychological and physical stability, escort/support-person coordination, discharge restrictions, overnight or post-session support, and follow-up contact when needed.
4 roles · 30 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaKetamine+3 moreEmergency recognition, escalation, and disposition planning
Teaches recognition of medical or psychiatric emergencies and the steps required to escalate care safely. The competency includes de-escalation, clinical consultation, 911 or emergency department transfer, serious-event escalation, and referral to appropriate higher-level care.
7 roles · 29 guidelines · 3 courses · 3 providers
5-MeO-DMTDMT / AyahuascaIbogaine+4 moreBlinding, allocation concealment, and unblinding control
Teaches how to preserve blinded trial conduct across participant interactions, outcome collection, staff roles, and session procedures. The competency includes preventing accidental unblinding, minimizing bias, and using emergency unblinding only when clinically necessary.
6 roles · 29 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaKetamine+4 moreMedication, substance-use, washout, and taper management
Teaches review and management of concomitant medications, restricted therapies, prohibited substances, washout periods, tapering requirements, and abstinence expectations. The competency includes participant counseling, medication reconciliation, sponsor notification, and team coordination when restrictions affect safety or interpretability.
5 roles · 29 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaKetamine+3 moreStudy documentation, data integrity, and regulatory recordkeeping
Teaches accurate study documentation, source-record quality, secure data capture, Good Clinical Practice recordkeeping, IRB and sponsor documentation requirements, monitoring readiness, audit support, accountability, and retention obligations.
3 roles · 27 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+4 moreManualized psychedelic psychotherapy delivery
Teaches delivery of psychedelic-assisted psychotherapy according to an approved study manual across preparation, dosing, integration, and follow-up. The competency balances standardized structure with non-directive support for the participant’s therapeutic process.
4 roles · 25 guidelines · 3 courses · 2 providers
KetamineLSDMDMA+1 moreTherapeutic boundaries, professional conduct, and consent for touch
Teaches how to maintain clear relational and physical boundaries in emotionally vulnerable treatment settings. This includes professional conduct, rapport without overreach, explicit consent for touch, the right to revoke consent, and strict prohibition of sexual or erotic contact.
7 roles · 24 guidelines · 4 courses · 3 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreCo-therapist and multidisciplinary team coordination
Teaches coordinated practice across co-therapists, physicians, psychiatrists, study coordinators, principal investigators, and other care-team members. The focus is shared responsibility, clear communication, role clarity, and coordinated observation of participant status.
4 roles · 24 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+4 morePhysical safety monitoring
Cluster covering 3 related competencies including: Physical safety monitoring, Safety monitoring during dosing sessions, Medical safety monitoring during psilocybin administration.
5 roles · 19 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+2 moreAcute psychiatric and behavioral risk monitoring
Teaches continuous monitoring for distress, confusion, psychotic symptoms, suicidality, agitation, and other acute behavioral risks during and after dosing. The focus is early recognition, documentation, and escalation to clinical support when risk emerges.
5 roles · 17 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaKetamine+3 morePreparation support
Cluster covering 11 related competencies including: Preparation support, Psilocybin preparation, Therapeutic preparation.
3 roles · 16 guidelines · 6 courses · 5 providers
5-MeO-DMTDMT / AyahuascaIbogaine+4 moreEthical conduct in human-subject research
Able to practice ethically in a clinical trial environment involving a Schedule-sensitive psychoactive intervention. This includes protecting participants, adhering to protocol, and supporting valid informed participation.
3 roles · 16 guidelines · 0 courses · 0 providers
DMT / AyahuascaIbogaineLSD+3 moreSupportive nondirective therapeutic stance
Cluster covering 6 related competencies including: Therapeutic support during dosing, Nondirective dosing-session presence, Supportive dosing-session facilitation.
2 roles · 16 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaMDMA+1 moreTherapeutic alliance building
Cluster covering 2 related competencies including: Therapeutic alliance building, Therapeutic alliance and rapport building.
2 roles · 15 guidelines · 1 courses · 1 providers
5-MeO-DMTDMT / AyahuascaMDMA+1 moreGood Clinical Practice and protocol procedure compliance
Teaches adherence to Good Clinical Practice, assigned study roles, protocol procedures, delegation boundaries, and applicable research regulations. The competency supports consistent execution of approved procedures across sites and participants.
4 roles · 15 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaKetamine+2 morePsilocybin session facilitation
Cluster covering 9 related competencies including: Psilocybin facilitation, Psilocybin session support, Psilocybin facilitation basics.
6 roles · 14 guidelines · 6 courses · 5 providers
LSDPsilocybinAdverse effects and side-effect management
Teaches recognition and management of expected and unexpected side effects during psychedelic or ketamine treatment. The competency emphasizes active observation, supportive response, and clinical escalation when symptoms exceed routine tolerability.
6 roles · 14 guidelines · 1 courses · 1 providers
DMT / AyahuascaIbogaineKetamine+3 morePsychedelic-assisted psychotherapy preparation and integration
Teaches structured pre-dose preparation and post-dose integration as the therapeutic frame for psychedelic-assisted psychotherapy. The therapist supports rapport, intention clarification, meaning-making, emotional processing, and consolidation of insights after dosing.
6 roles · 13 guidelines · 2 courses · 2 providers
5-MeO-DMTDMT / AyahuascaKetamine+3 moreHallucinogen pharmacology and effects
Cluster covering 7 related competencies including: Physiologic safety awareness, Hallucinogen pharmacology and effects, Hallucinogen-assisted therapy knowledge.
4 roles · 13 guidelines · 0 courses · 0 providers
LSDPsilocybinKetamine psychotherapy delivery
Cluster covering 12 related competencies including: KAP psychotherapy delivery, Ketamine and KAP knowledge, Ketamine integration planning.
6 roles · 12 guidelines · 7 courses · 5 providers
KetamineDissociation and acute neuropsychiatric effect monitoring
Teaches recognition and documentation of dissociation, psychosis-like symptoms, mania, and other acute neuropsychiatric effects that can occur after ketamine, psychedelic dosing, or related interventions. The focus is monitoring, reporting, and escalation when symptoms become clinically significant.
5 roles · 12 guidelines · 0 courses · 0 providers
DMT / AyahuascaIbogaineKetamine+1 morePhysiologic monitoring, thermoregulation, hydration, and overdose response
Teaches monitoring and response for acute physiological risks, including vital signs, temperature, hydration, overheating, excessive fluid intake, and suspected overdose. The competency emphasizes supportive care, medical coordination, documentation, and escalation when needed.
6 roles · 11 guidelines · 0 courses · 0 providers
DMT / AyahuascaKetamineMDMA+1 moreSpecial-interest adverse event vigilance
The protocol requires active monitoring for psychedelic-specific adverse events such as hallucinations, psychotic symptoms, dissociation, mood alteration, and cognitive disturbance. These require immediate notification and follow-up.
3 roles · 11 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+3 moreDepression symptom and remission monitoring
Teaches structured monitoring of depressive symptoms, response, and remission across treatment and follow-up. Learners use standardized scales and clinical review to track change and identify deterioration or non-response.
2 roles · 10 guidelines · 0 courses · 0 providers
IbogaineKetamineLSD+1 moreMindfulness, intention-setting, set and setting, and somatic presence
Teaches practices that support preparation and therapeutic presence, including mindfulness, intention-setting, body-aware attention, environmental preparation, mindset awareness, and regulation through somatic presence.
6 roles · 9 guidelines · 7 courses · 6 providers
5-MeO-DMTDMT / AyahuascaIbogaine+4 moreTrauma-informed therapeutic presence and somatic support
Teaches a trauma-informed stance during psychedelic work, including calm presence, non-verbal reassurance, body-aware support, somatic orientation, and containment through difficult experiences while maintaining safety and boundaries.
2 roles · 9 guidelines · 2 courses · 2 providers
KetamineMDMAPsilocybinComprehensive psychiatric assessment
Ability to perform or supervise detailed psychiatric evaluation for diagnosis, eligibility, and ongoing monitoring. The therapist/facilitator must understand symptom presentations relevant to MDD, AUD, suicidality, psychosis, and dissociation.
3 roles · 9 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+2 moreGrounding and regulation techniques
Therapists must be able to teach and coach grounding practices that help participants regulate during preparation and dosing. These methods are used before medication and during distress.
2 roles · 9 guidelines · 0 courses · 0 providers
MDMAPsilocybinOutcome Measure and Assessment Literacy
Teaches clinicians and research staff to understand the purpose, limits, scoring, interpretation, and clinical meaning of psychological measures and study instruments used to evaluate symptoms, functioning, safety, and treatment outcomes.
3 roles · 9 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaKetamine+2 moreClient preparation and therapeutic set/setting
Cluster covering 2 related competencies including: Preparation of set and setting, Client preparation and therapeutic set/setting.
3 roles · 8 guidelines · 2 courses · 2 providers
DMT / AyahuascaKetamineLSD+2 moreContinuation, discontinuation, and risk-benefit judgment
Teaches how clinicians determine whether a participant should proceed, pause, discontinue dosing, or terminate study participation. The competency centers on safety-driven clinical judgment, risk-benefit assessment, and early termination when continuation is no longer appropriate.
5 roles · 8 guidelines · 0 courses · 0 providers
KetamineMDMAPsilocybinParticipant safety restriction counseling
Teaches how to instruct participants on post-dose and study-period restrictions that reduce risk from impaired judgment, unsafe activity, prohibited substances, or behaviors that could confound study outcomes.
3 roles · 8 guidelines · 0 courses · 0 providers
5-MeO-DMTIbogaineKetamine+2 morePhysiologic monitoring during ketamine administration
Cluster covering 2 related competencies including: Safety monitoring during ketamine dosing, Physiologic monitoring during ketamine administration.
4 roles · 8 guidelines · 0 courses · 0 providers
KetaminePsychedelic-assisted therapy facilitation
Cluster covering 2 related competencies including: Psychedelic-assisted therapy facilitation, Group facilitation in a psychedelic setting.
3 roles · 8 guidelines · 0 courses · 0 providers
DMT / AyahuascaKetamineLSD+2 morePsychological support during altered states
Provides supportive therapeutic presence while the patient is under the influence of ketamine. Uses calming, noncoercive guidance to help the patient navigate dissociation and emotional material.
3 roles · 8 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+3 moreUse outcome assessment and follow-up to evaluate response
The study used standardized anxiety measures and followed patients for 2 months and 12 months, implying competence in tracking outcomes over time. Therapists should be able to assess symptom change and sustained benefit using structured follow-up.
2 roles · 8 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+2 moreVital sign and physical distress monitoring
Monitors participant physical status during study visits and identifies concerning changes requiring escalation. Vital signs and symptomatic changes are part of routine safety observation.
4 roles · 8 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+1 moreCultural humility, Indigenous respect, and equity-oriented care
Teaches culturally responsive psychedelic care, including humility, anti-bias practice, Indigenous and traditional-use awareness, cultural appropriation concerns, diversity and inclusion, and respectful work with marginalized communities.
6 roles · 7 guidelines · 11 courses · 10 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreTransference, countertransference, and therapist self-awareness
Teaches recognition and management of relational dynamics that can intensify in psychedelic-assisted therapy. Learners develop self-awareness around countertransference, projection, attachment, dependency, and other therapeutic-process risks.
3 roles · 7 guidelines · 1 courses · 1 providers
5-MeO-DMTKetamineMDMA+1 moreClinical Interviewing and PTSD Assessment
Teaches structured clinical interviewing and assessment administration for PTSD and related symptom domains, including symptom severity, functional impairment, risk factors, and appropriate use of standardized assessment tools.
2 roles · 7 guidelines · 0 courses · 0 providers
KetamineMDMADose escalation decision support
The therapist/facilitator must support structured dose escalation decisions within the individualized dosing regimen. Decisions depend on both patient-reported peak experience and clinical tolerability/safety judgments.
2 roles · 7 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+1 moreMedical escalation and rescue medication coordination
Cluster covering 2 related competencies including: Medical escalation and rescue medication use, Medical escalation and rescue medication coordination.
4 roles · 7 guidelines · 0 courses · 0 providers
5-MeO-DMTPsilocybinSafe Therapeutic Container Creation
Teaches providers to create and maintain a psychologically and physically safe therapeutic setting through clear structure, preparation, boundaries, attunement, environmental design, and ongoing attention to participant safety.
4 roles · 6 guidelines · 2 courses · 2 providers
5-MeO-DMTDMT / AyahuascaKetamine+2 moreIntegration and post-session debriefing
Cluster covering 4 related competencies including: Integration and debriefing, Integration and debriefing facilitation, Integration and post-session debriefing.
2 roles · 6 guidelines · 0 courses · 0 providers
DMT / AyahuascaPsilocybinKetamine infusion monitoring
Cluster covering 5 related competencies including: Cardiac safety monitoring, Ketamine infusion monitoring, Ketamine infusion administration.
3 roles · 6 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+1 moreMedical screening and medication review
Therapists/investigators must understand the medical suitability requirements for LSD-assisted psychotherapy and coordinate medication washout and concomitant medication review. This includes recognizing drug-drug interaction risks and contraindications.
3 roles · 6 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+2 moreMedication taper and withdrawal monitoring
Teaches monitoring during down-titration or discontinuation of psychiatric medications before dosing. Learners track withdrawal symptoms, symptom worsening, suicidality, and other risks that may emerge during tapering.
4 roles · 6 guidelines · 0 courses · 0 providers
IbogainePsilocybinProfessional boundaries and recording consent
Therapists may record sessions only with explicit participant consent and must handle recordings for training and research within protocol limits. Recording is part of the therapeutic and scientific framework, not routine clinical use.
3 roles · 6 guidelines · 0 courses · 0 providers
5-MeO-DMTLSDMDMA+1 moreReproductive risk, contraception, and pregnancy monitoring
Teaches counseling and monitoring around contraception, reproductive restrictions, pregnancy risk, and pregnancy-related discontinuation rules. Learners are trained to explain requirements clearly and respond promptly when pregnancy or reproductive-safety concerns arise.
2 roles · 6 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaKetamine+1 moreSafe treatment-setting facilitation
Provide a calm and supportive environment during treatment to reduce distress and support tolerance of the experience. The case report notes food, rest, and a quiet place as part of care.
2 roles · 6 guidelines · 0 courses · 0 providers
DMT / AyahuascaIbogaineMescalineTherapeutic rapport building
Cluster covering 4 related competencies including: Therapeutic rapport building, Rapport building and trust development, Therapeutic rapport and trust building.
2 roles · 6 guidelines · 0 courses · 0 providers
5-MeO-DMTLSDPsilocybinPsilocybin psychotherapy framework
Cluster covering 4 related competencies including: Psychedelic therapy workflow, Psilocybin psychotherapy framework, Psilocybin-assisted psychotherapy framework.
6 roles · 5 guidelines · 4 courses · 2 providers
DMT / AyahuascaKetaminePsilocybinEthical psychedelic facilitation
Cluster covering 3 related competencies including: Ethical psychedelic facilitation, Safe, legal psychedelic care facilitation, Ethical decision-making in psychedelic facilitation.
7 roles · 5 guidelines · 2 courses · 2 providers
5-MeO-DMTIbogaineKetamine+1 moreSession facilitation and therapeutic holding
Cluster covering 2 related competencies including: Session facilitation and therapeutic holding, Session facilitation and support during intense experiences.
3 roles · 5 guidelines · 2 courses · 2 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreManagement of concomitant medication interactions
Cluster covering 5 related competencies including: Concomitant medication review, Contraindication and interaction awareness, Contraindications, drug effects, and interactions.
4 roles · 5 guidelines · 1 courses · 1 providers
IbogaineLSDPsilocybinAssessment administration and interpretation
Ability to administer and interpret structured interviews, clinician ratings, and self-report measures used in the study. Therapists contribute to eligibility, safety, and outcome assessment.
2 roles · 5 guidelines · 0 courses · 0 providers
LSDPsilocybinEvaluate clinically significant response and treatment outcomes
Therapists/facilitators should be able to judge whether therapeutic change reaches clinically meaningful thresholds, not just whether symptoms improve numerically. This supports informed ongoing care and communication about benefits and limitations.
2 roles · 5 guidelines · 0 courses · 0 providers
5-MeO-DMTKetamineLSD+2 moreMatch dose and setting to patient capacity
Therapists/facilitators need judgment about dosing and setting so experiences remain tolerable and therapeutically useful. The paper repeatedly notes that when dose and setting are appropriate, emerging material remains within the patient’s capacity to cope.
2 roles · 5 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaLSD+2 moreParticipant education and informed consent communication
Clinicians and research staff must clearly educate participants about study procedures, risks, side effects, restrictions, and possible benefits, and obtain written informed consent before screening and study participation. Ethical delivery depends on transparent communication and opportunities for questions.
2 roles · 5 guidelines · 0 courses · 0 providers
DMT / AyahuascaIbogaineKetamine+2 moreParticipant safety planning and support network coordination
Can identify and involve support persons, attendants, and outside providers to enhance safety. The facilitator must coordinate practical supports while respecting confidentiality and protocol boundaries.
3 roles · 5 guidelines · 0 courses · 0 providers
MDMAPsilocybinProvide overnight and next-day containment
Therapists must ensure continuity of care after the acute session, including overnight observation and next-morning integration before discharge. This reflects a containment and recovery responsibility beyond the dosing period.
3 roles · 5 guidelines · 0 courses · 0 providers
DMT / AyahuascaIbogaineLSD+2 moreResearch assessment administration
Administer study measures and structured assessments on schedule, including psychological, spiritual, and neurobehavioral instruments. This includes both paper-based and Storyline-based assessments.
2 roles · 5 guidelines · 0 courses · 0 providers
KetamineMDMAPsilocybinRespect autonomy and individualized communication preferences
Adapt language and interpersonal style to the patient’s preferences to promote dignity and comfort. The therapist should also respect the patient’s autonomy within safety limits.
2 roles · 5 guidelines · 0 courses · 0 providers
IbogaineKetamineMDMA+1 moreRisk screening and exclusion judgment
Know the medical and psychiatric exclusions that protect participants from foreseeable harm. Facilitators must recognize conditions that make MDMA-assisted psychotherapy unsafe or inappropriate.
3 roles · 5 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+2 moreUnderstand dose-response and time course
The facilitator should know how oral and intravenous dosing relate to onset, duration, and peak effects. This knowledge supports proper session planning, monitoring, and integration timing.
2 roles · 5 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaLSD+3 moreRisk evaluation and safety monitoring
Teaches continuous evaluation of clinical risk and maintenance of a safe care environment throughout preparation, dosing, and follow-up. Learners monitor risk signals, apply safety procedures, and escalate care when needed.
6 roles · 4 guidelines · 3 courses · 2 providers
5-MeO-DMTIbogaineKetamine+2 moreMusic and therapist-variable awareness
The course explicitly mentions the role of music and therapist variables in treatment. Learners are expected to understand how these elements influence the PAP experience and therapeutic outcome.
3 roles · 4 guidelines · 1 courses · 1 providers
KetamineMDMATherapeutic touch judgment
The training includes appropriate use of therapeutic touch as part of safe delivery. Learners are expected to use touch judiciously and within ethical boundaries.
4 roles · 4 guidelines · 1 courses · 1 providers
MDMAControlled-substance handling awareness
Understands that MDMA is a Schedule 1 investigational product and must be stored, dispensed, and accounted for under regulatory control. Supports compliant handling during the session.
2 roles · 4 guidelines · 0 courses · 0 providers
KetamineMDMAPsilocybinDosage judgment and administration safety
Competent facilitation requires practical knowledge of dosage ranges, initial dosing, boosters, formulation handling, and administration errors. The handbook stresses both clinical judgment and meticulous procedural care.
2 roles · 4 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+1 moreFacilitate integration of experience into behavioral change
Cluster covering 2 related competencies including: Integration of psychedelic experience with behavior change, Facilitate integration of experience into behavioral change.
2 roles · 4 guidelines · 0 courses · 0 providers
5-MeO-DMTPsilocybinIndependent outcome assessment administration
The facilitator must administer and coordinate patient-rated and clinician-rated measures while minimizing bias. Assessments should be completed independently and in the correct order.
3 roles · 4 guidelines · 0 courses · 0 providers
DMT / AyahuascaIbogaineKetamine+1 moreManage agitation and elopement risk
Respond to agitation or attempts to leave the room in a way that preserves safety for the patient and others. The therapist should use containment, redirection, and escalation protocols when needed.
3 roles · 4 guidelines · 0 courses · 0 providers
5-MeO-DMTLSDMDMA+1 moreMDMA administration oversight
Study clinicians are responsible for administering study drug, ensuring correct dose assignment, and supervising safe oral ingestion during blinded sessions. This includes verifying visit-specific randomization information and ensuring dosing is delivered under the blinded workflow.
2 roles · 4 guidelines · 0 courses · 0 providers
IbogaineMDMAMescalineMonitor acute and short-term adverse effects
The study emphasizes the absence of acute or chronic adverse effects persisting beyond 1 day and no treatment-related serious adverse events, indicating the need for active monitoring during and after treatment. Facilitators must be able to observe, document, and respond to adverse reactions.
2 roles · 4 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaine+1 moreNarrative elicitation and phenomenological listening
Therapists must be able to elicit a full account of the dosing experience without overinterpreting it. The goal is to help participants remember, narrate, and reflect on their experience in detail.
2 roles · 4 guidelines · 0 courses · 0 providers
5-MeO-DMTPsilocybinPre-session dosing behavior instructions
Teaches clear communication of behavioral requirements before dosing sessions so conditions are standardized and preventable risks are reduced. Staff confirm that participants understand and follow pre-session instructions.
3 roles · 4 guidelines · 0 courses · 0 providers
KetaminePsilocybinPsilocybin psychoeducation
Cluster covering 2 related competencies including: Psilocybin psychoeducation, Psychedelic psychoeducation and expectation management.
2 roles · 4 guidelines · 0 courses · 0 providers
MDMAPsilocybinRecognition of contraindications and risk states
Therapists/facilitators must know the psychiatric and medical conditions that make KPT unsafe or inappropriate. Safe practice depends on excluding high-risk individuals.
2 roles · 4 guidelines · 0 courses · 0 providers
5-MeO-DMTKetamineMescaline+1 moreStructured symptom rating administration
Facilitators must competently administer and interpret clinician-rated ADHD and global severity measures. Accurate scoring is essential because these scales determine eligibility and outcomes.
3 roles · 4 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaLSDSubstance use assessment
Ability to evaluate alcohol and other substance use patterns using standardized tools and clinical interview. This is essential for eligibility, safety, and outcome monitoring.
2 roles · 4 guidelines · 0 courses · 0 providers
IbogaineKetamineMDMA+1 moreCrisis and adverse-event response
The page signals training in managing difficult or high-risk moments, including crisis intervention and trigger management. Learners are expected to respond appropriately when a session becomes destabilizing or unsafe.
6 roles · 3 guidelines · 1 courses · 1 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreSafety monitoring and emergency awareness
The page points to checklists and a guide to basic medical emergencies, indicating that learners should be able to monitor safety and recognize urgent issues. The overall training context also stresses keeping both client and practitioner safe.
5 roles · 3 guidelines · 1 courses · 1 providers
DMT / AyahuascaIbogaineMDMAAssess outcomes and psychological change
The framework implies competence in evaluating both symptom change and subjective outcomes over time. The study used standardized anxiety measures and qualitative interviews to assess sustained effects and patient-reported change.
2 roles · 3 guidelines · 0 courses · 0 providers
DMT / AyahuascaIbogaineLSDBlinded Assessment and Independent Rating
Teaches the use of independent or blinded assessors to reduce expectancy and observer bias, preserve separation between therapeutic and rating roles, manage unblinding risks, and protect outcome validity in open-label or partially blinded designs.
3 roles · 3 guidelines · 0 courses · 0 providers
5-MeO-DMTKetamineMDMACardiac risk monitoring
Monitor for ibogaine-associated cardiac toxicity, especially QTc prolongation and risk of torsades de pointes. This includes baseline exclusion screening, frequent ECG surveillance, and escalation when QTc becomes markedly prolonged.
2 roles · 3 guidelines · 0 courses · 0 providers
IbogaineElicit and formulate positive intentions
Help the patient identify personally meaningful, positive intentions to guide the session and future change. Intentions should be active, concrete, and framed toward desired gains rather than avoidance.
2 roles · 3 guidelines · 0 courses · 0 providers
5-MeO-DMTPsilocybinInformed consent and treatment briefing
Therapists/facilitators must support ethically valid informed consent by ensuring participants understand the intervention, expectations, risks, and logistics. They also provide anticipatory guidance before ketamine sessions and discharge information after dosing.
2 roles · 3 guidelines · 0 courses · 0 providers
DMT / AyahuascaIbogaineKetamineInformed consent responsibility
Facilitators are responsible for ensuring that participants have provided informed consent before receiving MDMA-assisted therapy. This reflects an ethical and regulatory duty central to work with investigational treatments.
2 roles · 3 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaMDMAInformed preparation and orientation of the subject
The therapist is responsible for giving truthful, individualized preparation and reassurance about the experience, including likely sensations, risks of resistance, and expectations for conduct. The preparation aims to reduce fear, improve cooperation, and support voluntary participation.
2 roles · 3 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaLSDInterdisciplinary coordination across mental health and medical services
Combined ketamine infusion and PE treatment requires coordination between psychotherapy providers and medical/anesthesia or medication administration staff. Effective collaboration supports timing, safety oversight, and protocol fidelity.
3 roles · 3 guidelines · 0 courses · 0 providers
DMT / AyahuascaKetamineKnowledge of ayahuasca pharmacology and effects
Understand the basic pharmacology and clinical effects of ayahuasca to inform safe facilitation and interpretation of responses. The source identifies dimethyltryptamine as a 5-HT2A agonist and harmine as a monoamine-oxidase A inhibitor.
2 roles · 3 guidelines · 0 courses · 0 providers
DMT / AyahuascaKnowledge of MDMA effects and risks
Facilitators must understand the expected psychological, physiological, and potential adverse effects of MDMA in order to prepare participants, support the session, and detect complications.
3 roles · 3 guidelines · 0 courses · 0 providers
MDMAMRI safety screening and imaging-session coordination
Teaches screening for MRI contraindications and coordination of imaging clearance before scan procedures. The competency prevents exposure of ineligible participants to magnetic-resonance risks and supports safe imaging-session logistics.
3 roles · 3 guidelines · 0 courses · 0 providers
MDMAPsilocybinOpioid withdrawal assessment
Evaluates opioid withdrawal symptoms and tracks changes over time in participants discontinuing methadone OST. Uses standardized withdrawal ratings to assess potential treatment effects and safety.
2 roles · 3 guidelines · 0 courses · 0 providers
IbogainePre-treatment clinical risk assessment
Understand the major medical risks associated with ibogaine administration, especially cardiac and neurologic toxicity, before proceeding with treatment. This includes recognizing that ibogaine has been linked to torsades de pointes, QTc prolongation, bradycardia, and ataxia.
3 roles · 3 guidelines · 0 courses · 0 providers
IbogainePsychoeducation about MDMA effects and session trajectory
Therapists must understand MDMA’s expected subjective, interpersonal, and physiological effects and prepare participants accordingly. This knowledge supports normalization, reassurance, and effective use of the medicine within therapy.
2 roles · 3 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaMDMAPsychological preparation and anxiety reduction
Facilitators need practical skills in preparing participants emotionally for ketamine administration and reducing distress. The protocol highlights relaxation, breathing, and grounding strategies to reduce anxiety or discomfort associated with the drug experience.
2 roles · 3 guidelines · 0 courses · 0 providers
DMT / AyahuascaKetaminePsychological state assessment
Administer and interpret psychological and psychometric measures relevant to mood, cravings, expectations, mystical experience, ego dissolution, and functioning. Facilitators must accurately support questionnaire-based assessment across time points.
2 roles · 3 guidelines · 0 courses · 0 providers
DMT / AyahuascaLSDMescaline+1 moreResearch rating fidelity
Ability to administer standardized clinical ratings consistently and under supervision. Reliable measurement is essential for efficacy and safety endpoints.
4 roles · 3 guidelines · 0 courses · 0 providers
5-MeO-DMTIbogaineKetamineSafety monitoring of vital signs and cardiovascular effects
Monitor and respond to the expected sympathomimetic effects of MDMA. The therapist/facilitator must be alert to transient increases in blood pressure, pulse, and related cardiac symptoms.
2 roles · 3 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaMDMASetting optimization
Create an environment that supports safety, comfort, and relaxation during the session. The setting is deliberately structured to reduce anxiety and facilitate a positive experience.
2 roles · 3 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaIbogaineSupport safe administration of LSD dosing sessions
Because the protocol involved specific LSD doses, active placebo control, and session spacing, facilitators need applied skill in implementing dosing-session procedures safely and consistently. This includes maintaining therapeutic support while adhering to protocol constraints.
2 roles · 3 guidelines · 0 courses · 0 providers
LSDMescalineTeach and apply stress inoculation and anxiety support
Therapists should identify or teach in-session coping tools and collaboratively plan how anxiety states will be recognized and supported.
2 roles · 3 guidelines · 0 courses · 0 providers
5-MeO-DMTMDMAPsilocybinTherapeutic alliance and trust building
The therapist must create an atmosphere of confidence and mutual understanding before ketamine administration. This relationship is treated as a key therapeutic factor in the protocol.
1 role · 3 guidelines · 0 courses · 0 providers
IbogaineKetaminePsilocybinTherapeutic rapport and engagement support
Help patients engage in emotionally intense trauma-focused treatment and reduce dropout risk. The therapist should recognize comorbid depression or anxiety that may interfere with adherence and response.
2 roles · 3 guidelines · 0 courses · 0 providers
DMT / AyahuascaKetamineMDMATraining and certification in study instruments
Teaches the requirement for site personnel to be trained and certified on protocol-specific assessments, psychiatric instruments, rating scales, and study procedures before performing them in the trial.
3 roles · 3 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaKetamine+1 moreTrauma treatment background
Therapists need a solid professional background in psychotherapy, especially PTSD treatment. Prior experience with established trauma therapies and related approaches is considered important preparation for this work.
2 roles · 3 guidelines · 0 courses · 0 providers
MDMATRD eligibility assessment
Understands and applies the protocol-defined criteria for treatment-resistant major depressive disorder, including diagnostic confirmation, episode severity, and prior treatment failure requirements. Must verify both current and historical antidepressant nonresponse and ensure the participant remains eligible at baseline.
2 roles · 3 guidelines · 0 courses · 0 providers
5-MeO-DMTKetamineUnderstanding of trial procedures and schedule
Know the sequence, timing, and purpose of screening, preparation, dosing, scanning, follow-up, and unblinding visits. The therapist/facilitator must be able to work within the full protocol structure.
2 roles · 3 guidelines · 0 courses · 0 providers
MDMAPsilocybinHarm reduction and risk awareness
Cluster covering 5 related competencies including: Harm-reduction orientation, Harm reduction and risk awareness, Harm reduction for client support.
7 roles · 2 guidelines · 5 courses · 5 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 moreDosing-day facilitation
Cluster covering 2 related competencies including: Dosing-day facilitation, Dosing-session facilitation.
4 roles · 2 guidelines · 2 courses · 2 providers
DMT / AyahuascaKetaminePsilocybinLegal and Regulatory Navigation
Teaches practitioners to identify and apply relevant legal, regulatory, ethical, and institutional requirements, including documentation, consent, reporting, controlled-substance, and jurisdiction-specific obligations.
6 roles · 2 guidelines · 2 courses · 2 providers
IbogaineKetamineMDMA+1 moreGuided inquiry and reflective language
Students learn to use language and questions that deepen a client’s inner experience and support healing. This is a practical communication competency for facilitation and integration work.
2 roles · 2 guidelines · 1 courses · 1 providers
LSDMDMAPsilocybinACT-based case formulation
Therapists must understand participant distress through an Acceptance and Commitment Therapy lens and use that formulation throughout preparation, dosing, and integration. They identify psychological inflexibility processes and track movement toward or away from psychological flexibility.
1 role · 2 guidelines · 0 courses · 0 providers
PsilocybinAssess and engage support systems
Therapists should understand the participant’s support network and appropriately involve support persons when relevant and desired.
2 roles · 2 guidelines · 0 courses · 0 providers
MDMAAssessment of indications and contraindications
The therapist must exercise clinical judgment about who may benefit, who may have difficulty surrendering defenses, and where evidence is limited. The handbook emphasizes uncertainty, need for research, and cautious selection based on insecurity, rigidity, suspicion, diagnosis, and treatment goals.
2 roles · 2 guidelines · 0 courses · 0 providers
LSDAssessment-driven therapeutic tailoring
Uses assessment findings to individualize therapy and medication-session preparation. Adapts the approach based on participant response, goals, and clinical presentation.
1 role · 2 guidelines · 0 courses · 0 providers
KetaminePsilocybinBaseline history taking
Collect and interpret baseline behavioral, psychiatric, and medical history relevant to psilocybin research. This information is used to determine eligibility and contextualize outcomes.
2 roles · 2 guidelines · 0 courses · 0 providers
DMT / AyahuascaPsilocybinCeremonial framing and intentional therapeutic setting
Facilitators require skill in establishing ceremonial and intentional framing around ketamine sessions to support therapeutic depth and coherence. This includes preparing participants for the significance and structure of the experience within the group model.
1 role · 2 guidelines · 0 courses · 0 providers
KetamineCognitive safety monitoring
Ability to monitor for short-term cognitive impairment following psychedelic administration. The study included tests designed to detect decrements in attention and processing speed.
2 roles · 2 guidelines · 0 courses · 0 providers
5-MeO-DMTCollaboration with medical supervision
Therapists function within a medically supervised ketamine model and must coordinate closely with clinicians responsible for dosing oversight and safety clearance. This includes understanding role boundaries and supporting monitoring workflows.
3 roles · 2 guidelines · 0 courses · 0 providers
KetamineCompetence in protocol adherence for dosing sessions
The intervention involved two separate psilocybin dosing sessions 3 weeks apart under a randomized controlled protocol, implying the need for facilitators to reliably support treatment according to a fixed schedule and study procedures.
2 roles · 2 guidelines · 0 courses · 0 providers
DMT / AyahuascaPsilocybinConfidential and nonjudgmental therapeutic stance
Facilitators should create a safe interpersonal environment conducive to disclosure and processing. The setting is intentionally designed to support openness, comfort, and trust.
2 roles · 2 guidelines · 0 courses · 0 providers
DMT / AyahuascaPsilocybinDeliver mindfulness and grounding exercises
Use brief mindfulness practices and grounding strategies to stabilize attention and reduce distress before and during the session. These techniques help the patient reconnect to present-moment awareness and bodily sensation.
2 roles · 2 guidelines · 0 courses · 0 providers
DMT / AyahuascaPsilocybinManage mandated reporting and safety concerns
Therapists/facilitators must fulfill professional legal duties and escalate safety or reporting concerns promptly.
2 roles · 2 guidelines · 0 courses · 0 providers
KetamineMDMAMedication conversion and detoxification workflow
Coordinate the conversion from opioid maintenance treatment to morphine-sulphate prior to ibogaine dosing, reflecting the treatment sequence described in the study. This requires careful timing and clinical oversight.
2 roles · 2 guidelines · 0 courses · 0 providers
IbogaineNasal tolerability assessment
Performs targeted nasal examinations and assesses local tolerability of esketamine nasal spray. Identifies findings that could affect drug delivery, safety, or continuation.
2 roles · 2 guidelines · 0 courses · 0 providers
DMT / AyahuascaKetamineNausea and vomiting management
Recognize and respond to gastrointestinal adverse effects that may occur frequently with higher doses. Manage emesis to reduce aspiration risk, dehydration, and treatment disruption.
2 roles · 2 guidelines · 0 courses · 0 providers
MescalineIbogaineNighttime and overnight participant support
When overnight stays are required, facilitators and attendants must maintain safe observation and supportive presence without acting as outside therapists. They need to monitor comfort, safety, and emergency access overnight.
2 roles · 2 guidelines · 0 courses · 0 providers
MDMANon-responder handoff and continuity of care
The facilitator must ensure non-responders are transitioned safely back to clinical care. Continuity of care is explicitly required to support ongoing psychiatric treatment.
2 roles · 2 guidelines · 0 courses · 0 providers
KetaminePsilocybinOutcome and safety measure literacy
Knowledge of the trial’s primary, secondary, and exploratory endpoints and the instruments used to assess them. This enables accurate administration and interpretation of study procedures.
2 roles · 2 guidelines · 0 courses · 0 providers
DMT / AyahuascaKetaminePatient monitoring during ibogaine administration
Monitors patients closely during treatment because serious adverse outcomes may occur. Safety monitoring is essential given that one participant died during treatment in the study.
2 roles · 2 guidelines · 0 courses · 0 providers
IbogainePeak experience assessment
Ability to assess whether the target acute psychedelic experience has occurred using the study-defined scale and threshold. This was used to guide individualized dosing.
2 roles · 2 guidelines · 0 courses · 0 providers
5-MeO-DMTPharmacokinetic awareness
Understands the drug’s rapid absorption profile and lack of accumulation with repeated dosing. Uses this knowledge to anticipate timing of effects and safety observations.
2 roles · 2 guidelines · 0 courses · 0 providers
5-MeO-DMTMescalinePreparation for altered-state experience
A major therapist competency is preparing patients extensively for the ketamine session, including the nature of the special state of consciousness and possible ego dissolution or separation from the body. Preparation is both educational and psychotherapeutic.
1 role · 2 guidelines · 0 courses · 0 providers
KetamineMDMAProfessional licensure and supervision
Therapists must meet licensure requirements and work within supervision structures appropriate to their training and role. Unlicensed or PAP-inexperienced staff require direct supervision.
2 roles · 2 guidelines · 0 courses · 0 providers
DMT / AyahuascaPsilocybinProtocol adherence and visit scheduling
Ability to manage the study schedule, windows, and follow-up procedures accurately. This supports treatment delivery and valid outcome collection.
2 roles · 2 guidelines · 0 courses · 0 providers
DMT / AyahuascaKetamineRelapse prevention psychotherapy delivery
Deliver ongoing relapse prevention psychotherapy after dosing through the post-dose follow-up period. The approach is used to support alcohol recovery and translate treatment effects into behavior change.
1 role · 2 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaRetention and engagement skills
Given the risk of high attrition, facilitators need strong engagement and follow-up skills. The protocol explicitly notes the importance of respecting time commitments, tracking procedures, and strong interpersonal skills of study personnel.
1 role · 2 guidelines · 0 courses · 0 providers
5-MeO-DMTKetamineSafety monitoring for adverse effects
Monitors for potential adverse effects associated with ibogaine administration and the detoxification period, even though the abstract primarily reports outcomes rather than specific events.
2 roles · 2 guidelines · 0 courses · 0 providers
IbogaineSession pacing and timing
Therapists must pace the day appropriately, from early dosing to flexible termination, avoiding premature ending that could destabilize the subject. The handbook presents timing as an active facilitative skill rather than a logistical detail.
2 roles · 2 guidelines · 0 courses · 0 providers
5-MeO-DMTLSDShared decision-making and referral coordination
Collaborates with patients, medical practitioners, and referring providers to support individualized care. Helps patients consider alternatives and coordinate ongoing treatment needs.
3 roles · 2 guidelines · 0 courses · 0 providers
IbogaineKetamineTrack cognitive performance during treatment
Because cognitive performance during treatment is a named secondary outcome, clinicians involved in care should be able to monitor and document cognitive functioning relevant to treatment participation. This supports safety oversight and interpretation of treatment effects.
2 roles · 2 guidelines · 0 courses · 0 providers
5-MeO-DMTKetamineUnderstanding MDMA effects and non-linear healing
Therapists must have a thorough understanding of MDMA’s subjective, relational, and physiological effects, including the non-linear way these may support healing. This knowledge is necessary for preparation, in-session decisions, and normalization of participant experiences.
2 roles · 2 guidelines · 0 courses · 0 providers
MDMAUse of ACT and adjunctive psychotherapies
Apply Acceptance and Commitment Therapy as the primary psychotherapeutic framework, while using other modalities as clinically indicated. The protocol also references CBT, psychodynamic approaches, and Internal Family Systems.
1 role · 2 guidelines · 0 courses · 0 providers
KetaminePsilocybinUse of structured rating scales
The therapist/facilitator or designated rater must administer and interpret multiple structured clinical scales reliably. Training and separation of roles are required to preserve rating quality and blinding.
3 roles · 2 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaValues clarification and committed action coaching
Therapists must help participants identify, recover, and translate values into concrete behavior change. The manual treats values work as central to depression recovery and integration.
2 roles · 2 guidelines · 0 courses · 0 providers
PsilocybinWithdrawal symptom assessment
Measure opioid withdrawal severity using standardized instruments and interpret symptom severity over time. Facilitators must be able to collect both objective observation and patient-reported data.
2 roles · 2 guidelines · 0 courses · 0 providers
IbogaineWork within medically supervised settings
LSD-assisted psychotherapy in this study is explicitly framed as medically supervised. Therapists/facilitators need to practice within a setting capable of medical oversight and management of prolonged altered states.
4 roles · 2 guidelines · 0 courses · 0 providers
IbogaineLSDTrauma-informed care
Cluster covering 2 related competencies including: Trauma-informed care, Trauma-informed psychedelic care.
4 roles · 1 guidelines · 4 courses · 4 providers
KetaminePsilocybinPsychedelic integration support
Cluster covering 2 related competencies including: Psychedelic integration support, Psychedelic knowledge integration.
4 roles · 1 guidelines · 2 courses · 2 providers
DMT / AyahuascaPsychotherapeutic facilitation methods
Cluster covering 2 related competencies including: Facilitation of psychedelic journeys, Psychotherapeutic facilitation methods.
4 roles · 1 guidelines · 2 courses · 2 providers
LSDPsilocybinTrauma-informed practice
Cluster covering 2 related competencies including: Trauma-informed practice, Trauma-informed clinical practice.
2 roles · 1 guidelines · 2 courses · 1 providers
MDMAPsilocybinAccurate source limitation recognition
Ability to acknowledge when the source does not contain therapist or facilitator competency information. The extractor should not overstate what can be supported by the text.
2 roles · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTAcute monitoring of subjective intensity
Track the participant’s subjective drug intensity during the active phase of the session. This includes recognizing when the participant cannot respond and how to document maximum intensity.
2 roles · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaAdministration of vaporized 5-MeO-DMT
Ability to correctly deliver the investigational inhaled drug using standardized vaporization procedures and participant instructions. Safe and accurate administration is central to the dosing protocol.
2 roles · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaAlcohol abstinence screening and enforcement
Ensure required abstinence conditions are met before dosing and make clinical judgments about rescheduling or exclusion when they are not. This protects safety and protocol integrity.
2 roles · 1 guidelines · 0 courses · 0 providers
DMT / AyahuascaAssessment administration and sequencing
Administer study assessments in the correct order and in the correct format. The protocol depends on reliable, standardized administration by trained site personnel and central raters.
1 role · 1 guidelines · 0 courses · 0 providers
PsilocybinAssessment of psychological readiness and vulnerability
Before administration, facilitators should assess readiness and factors that could increase the chance of a difficult session. The source highlights that preoccupation, rigidity, low trust, and poor support can worsen experiences.
2 roles · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTAssessment of treatment response
Track onset, duration, and phases of ibogaine effects as part of clinical monitoring. The manual describes multiple stages of effect and expects the provider to observe them carefully.
2 roles · 1 guidelines · 0 courses · 0 providers
IbogaineAtaxia and neurologic monitoring
Assess for cerebellar adverse effects such as ataxia during and after ibogaine administration. The source indicates ataxia is likely driven by ibogaine exposure and should be tracked systematically.
2 roles · 1 guidelines · 0 courses · 0 providers
IbogaineAyahuasca pharmacology and dosing awareness
Facilitators need basic knowledge of ayahuasca composition, dosing, and interaction risks to support safe administration. The protocol emphasizes dose calculation, substance composition, and monitoring for contraindications.
1 role · 1 guidelines · 0 courses · 0 providers
DMT / AyahuascaBehavioral assessment administration
Trained staff must administer and/or supervise a battery of behavioral tasks and self-report instruments consistently across baseline and drug sessions. Some measures are verbally administered by clinicians or coordinators and require standardized delivery.
2 roles · 1 guidelines · 0 courses · 0 providers
MDMABoundary management in a dual-role therapeutic model
Navigate the combination of psychedelic support and AUD therapy while preserving clear therapeutic boundaries. The facilitator must deliver supportive care without role confusion or undue influence.
2 roles · 1 guidelines · 0 courses · 0 providers
DMT / AyahuascaCheck-in and timing of interventions during sessions
Therapists must skillfully time check-ins and interventions to sustain process without unnecessary intrusion. They monitor silence, talking, avoidance, and signs of internal engagement to decide when to inquire, redirect, or simply witness.
2 roles · 1 guidelines · 0 courses · 0 providers
MDMAClinical judgment for exclusion of high-risk patients
Exclude or defer patients whose medical risk is too high, especially those with cardiovascular disease or other major contraindications. This is central to safer administration according to the source.
2 roles · 1 guidelines · 0 courses · 0 providers
IbogaineClinical judgment on treatment optimization
Uses observed patient response to help optimize how ketamine-assisted psychotherapy is administered. Informs future clinical decisions about approach and dosing strategy.
2 roles · 1 guidelines · 0 courses · 0 providers
KetamineClinician therapist availability and scope
At least one therapist in the dyad must be a clinician with capability to assess and manage medical or psychiatric adverse events during the dosing session. This reflects a required competency boundary between general support and clinical responsibility.
2 roles · 1 guidelines · 0 courses · 0 providers
PsilocybinCollaboration with medical and nursing staff
Ketamine-assisted treatment in this protocol is multidisciplinary, so facilitators must work closely with study doctors and nurses. This includes coordinating preparation, understanding monitoring responsibilities, and escalating concerns appropriately.
1 role · 1 guidelines · 0 courses · 0 providers
KetamineControlled inhalation administration
Can safely administer vaporized GH001 using standardized equipment and procedure. Accurate delivery and participant instruction are essential to reliable dosing.
2 roles · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTCoordinate adjunctive ketamine or active placebo with psychotherapy timing
Facilitators and treating clinicians must understand and operationalize the study-specific timing between infusions and exposure sessions. This includes aligning infusion administration 24 hours before PE sessions during the first 3 weeks.
1 role · 1 guidelines · 0 courses · 0 providers
KetamineCOVID-19 infection control
Implement infection-prevention procedures during in-person study and dosing visits. Facilitators must screen participants, use PPE, maintain distancing when feasible, and adapt procedures based on test results or symptoms.
2 roles · 1 guidelines · 0 courses · 0 providers
PsilocybinCYP2D6 genotype-informed dosing
Use pharmacogenetic information to anticipate altered ibogaine metabolism and exposure. The study identifies CYP2D6 activity as a major determinant of ibogaine clearance.
2 roles · 1 guidelines · 0 courses · 0 providers
IbogaineDocumentation and note-taking
Document participant experiences and relevant observations to support continuity, recall, and study integrity. Notes may also serve as a participant memory aid after dosing sessions.
2 roles · 1 guidelines · 0 courses · 0 providers
PsilocybinDocumentation of subjective experience
The therapist/facilitator must record participant-reported effects and clinically relevant observations accurately. Documentation supports both safety monitoring and outcome interpretation.
2 roles · 1 guidelines · 0 courses · 0 providers
DMT / AyahuascaDose selection and regimen planning
Plan ibogaine dosing based on patient status, formulation, prior opioid exposure, and therapeutic goals. The manual presents both single-dose and multi-dose approaches and stresses patient-specific judgment.
1 role · 1 guidelines · 0 courses · 0 providers
IbogaineDose-response observation
Tracks dose-dependent changes without assuming full psychedelic effects. This includes recognizing that low-dose exposure may modulate brain activity while remaining sub-psychedelic.
2 roles · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTDrug interaction and mechanism awareness
Understand the role of serotonergic mechanisms and the implications of receptor antagonism for acute psychedelic effects. Use this knowledge to interpret responses and co-administration effects.
2 roles · 1 guidelines · 0 courses · 0 providers
MescalineElectrolyte and medical screening
Assess for physiologic factors that may increase ibogaine-related harm, especially electrolyte abnormalities. The source identifies electrolyte screening as part of safer administration.
2 roles · 1 guidelines · 0 courses · 0 providers
IbogaineEscitalopram monitoring and counseling
Understand the common and serious adverse effects, interaction risks, and monitoring needs of escitalopram. This includes cardiac, psychiatric, sexual, and withdrawal-related concerns.
2 roles · 1 guidelines · 0 courses · 0 providers
PsilocybinEthical supervision in experimental drug administration
Ensure that administration occurs within an ethically supervised research or clinical framework with informed oversight and careful risk-benefit consideration. Hallucinogenic agents require especially cautious use in vulnerable psychiatric populations.
1 role · 1 guidelines · 0 courses · 0 providers
DMT / AyahuascaHydration management
Prevent dehydration during and after ibogaine treatment. The manual stresses that patients may not feel like drinking and that dehydration can become dangerous, especially if vomiting occurs.
2 roles · 1 guidelines · 0 courses · 0 providers
IbogaineIbogaine treatment administration knowledge
Knows the use of ibogaine as a detoxification agent in medical and nonmedical settings and understands that its mechanism of action is novel and not fully established.
2 roles · 1 guidelines · 0 courses · 0 providers
IbogaineIbogaine-specific cardiac vigilance
Understand the unique cardiovascular hazards associated with ibogaine and the need for intensive cardiac oversight. The facilitator should know that cardiac risk is a central safety issue rather than a minor side effect.
3 roles · 1 guidelines · 0 courses · 0 providers
IbogaineDMT / AyahuascaIn-session emotional support
During ketamine administration, the therapist provides continuous emotional support while the patient reclines with eyeshades and music. This support helps the patient tolerate and make use of the psychedelic experience.
1 role · 1 guidelines · 0 courses · 0 providers
KetamineInformed consent administration
Therapists/facilitators must ensure participants are properly informed using approved consent materials before participation in MDMA-assisted psychotherapy research.
2 roles · 1 guidelines · 0 courses · 0 providers
MDMAInformed consent and ethical use in uncertain evidence
Use ibogaine only after a careful discussion of uncertain efficacy, limited research, and known risks. Ethical practice requires transparent communication about the experimental nature of treatment and the absence of robust clinical standards.
2 roles · 1 guidelines · 0 courses · 0 providers
IbogaineInformed oversight for vulnerable participants
Exercises heightened ethical responsibility when working with people with opioid dependence undergoing medication changes. Ensures participation remains voluntary, monitored, and clinically appropriate.
1 role · 1 guidelines · 0 courses · 0 providers
IbogaineInterpretation of neuroimaging-linked clinical findings
Understand that changes in cerebral blood flow were observed after ayahuasca intake in regions implicated in mood and emotion regulation. Facilitators should be able to contextualize these findings without overinterpreting them clinically.
2 roles · 1 guidelines · 0 courses · 0 providers
DMT / AyahuascaKnowledge of psychedelic session structure
Facilitators need to understand the full treatment sequence and how each phase contributes to safety and treatment delivery. The intervention depends on correct sequencing and timing.
2 roles · 1 guidelines · 0 courses · 0 providers
PsilocybinKnowledge of therapeutic mechanism and expected time course
The therapist/facilitator should know the expected onset, peak, and persistence of effects to guide monitoring and interpretation. The source reports acute effects with follow-up improvements lasting days.
2 roles · 1 guidelines · 0 courses · 0 providers
DMT / AyahuascaLSD psychotherapy administration
Ability to administer LSD in a psychotherapy setting using the regimen described in the source. The therapist/facilitator must understand session-based dosing and treatment course structure.
2 roles · 1 guidelines · 0 courses · 0 providers
LSDMaintain a post-session safety net
Therapists must provide continuity, availability, and clear support structures after MDMA sessions to reduce anxiety and manage emerging difficulties. This safety net extends beyond the dosing day.
2 roles · 1 guidelines · 0 courses · 0 providers
MDMAManagement of dual relationships and undue influence
Therapists must protect voluntariness when potential participants are also their patients. Independent evaluation should be used to reduce pressure or perceived coercion in recruitment and consent.
2 roles · 1 guidelines · 0 courses · 0 providers
MDMAManagement of hypertension and cardiovascular complications
Therapists in this setting must recognize abnormal cardiovascular responses and follow protocolized responses for hypertensive crisis, angina, myocardial infarction, or stroke.
2 roles · 1 guidelines · 0 courses · 0 providers
MDMAManagement of psychological distress
Facilitators must be able to contain and support intense psychological distress during the session. The study notes that the experience could be emotionally difficult even when participants felt safe.
2 roles · 1 guidelines · 0 courses · 0 providers
DMT / AyahuascaManaging short-duration high-intensity sessions
5-MeO-DMT produces a very short but intense experience, which changes facilitation demands. Facilitators must be prepared for rapid transitions into and out of the altered state.
1 role · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaMedical contraindication screening
Recognizes medical factors that may increase risk during inhaled 5-MeO-DMT administration. Medical clearance is required before dosing.
2 roles · 1 guidelines · 0 courses · 0 providers
DMT / Ayahuasca5-MeO-DMTMedication reconciliation and interaction management
Therapists must understand clinically significant drug interactions with ibogaine, including QT-prolonging, serotonergic, centrally acting, and CYP2D6-related medications. This knowledge informs screening, tapering, and dosing decisions.
2 roles · 1 guidelines · 0 courses · 0 providers
IbogaineMonitoring and documentation of device-related issues
Because study drug delivery uses a vaporization device, staff must be able to recognize, document, and escalate device deficiencies. Device issues may have safety implications even when no patient harm occurs.
2 roles · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaNasal administration awareness
Understand the intranasal administration procedure and related local adverse effects. The facilitator must support safe delivery and monitor nasal reactions.
1 role · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTOn-site physician emergency competence
A study physician with psychiatric and cardiovascular emergency expertise must be available during dosing. This reflects a requirement for advanced emergency readiness and clinical judgment.
1 role · 1 guidelines · 0 courses · 0 providers
KetamineOngoing informed consent
Treat consent as a continuing process rather than a one-time event. Patients must understand the treatment and retain the ability to revoke consent, with special procedures during the medication session for safety.
2 roles · 1 guidelines · 0 courses · 0 providers
MDMAOperational prioritization of assessments
Sequences study procedures correctly to reduce bias and protect participant safety. Particularly prioritizes PROs, clinician ratings, and dosing-day procedures in the required order.
2 roles · 1 guidelines · 0 courses · 0 providers
KetamineOverdose, misuse, and abuse-liability vigilance
Facilitators are expected to monitor for signs of misuse, diversion, dependence, or other abuse-related phenomena even though the medication is administered only on-site. They must also recognize protocol violations or dropout patterns that may signal abuse liability concerns.
1 role · 1 guidelines · 0 courses · 0 providers
MDMAParticipant preparation and procedural guidance
Prepare participants for the dosing session and guide them through standardized procedures. The facilitator should ensure readiness, adherence to study rules, and smooth progression through the session schedule.
1 role · 1 guidelines · 0 courses · 0 providers
MescalineParticipant preparation for medication adherence
Prepare participants to correctly use nicotine replacement therapy when assigned to the control arm. Facilitators must provide education, dosing instructions, and side-effect guidance.
2 roles · 1 guidelines · 0 courses · 0 providers
PsilocybinPharmacokinetic literacy
Understands core pharmacokinetic concepts needed to interpret study findings and guide safety observation. Recognizes dose-linear exposure changes and elimination characteristics relevant to monitoring windows.
2 roles · 1 guidelines · 0 courses · 0 providers
IbogainePre-session medical screening
The therapist/facilitator must ensure medical suitability before ayahuasca administration by checking for conditions that increase risk. Screening should include physical exam, laboratory testing, and pregnancy assessment when indicated.
2 roles · 1 guidelines · 0 courses · 0 providers
DMT / AyahuascaPreparation for ketamine sessions
Therapists must prepare participants psychologically and practically for ketamine dosing through rapport-building, psychoeducation, expectation-setting, and intention development. Preparation is emphasized because of trauma burden, psychiatric comorbidity, and instability in the target population.
1 role · 1 guidelines · 0 courses · 0 providers
KetamineProduct identity verification
Verify the formulation and potency of the ibogaine product before administration. The manual warns that confusion between HCl, extract, and root bark can cause underdosing or fatal overdosing.
2 roles · 1 guidelines · 0 courses · 0 providers
IbogaineProtocol adherence and dose conditions
Follows the study's operational rules for dose timing, progression, and stopping conditions. Reliable execution is necessary for both safety and interpretability of results.
2 roles · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTProvide structured psychological support alongside treatment
All patients in the trial received psychological support in conjunction with medication administration, indicating that facilitators must be able to deliver structured supportive care as part of the treatment model.
2 roles · 1 guidelines · 0 courses · 0 providers
PsilocybinQuetiapine XR augmentation management
Initiates, uptitrates, and monitors quetiapine XR augmentation in the comparator arm according to age-specific schedules and tolerability. Recognizes the therapeutic minimum and discontinuation triggers.
1 role · 1 guidelines · 0 courses · 0 providers
KetamineReactivation event assessment
Identify and document possible post-dose reactivation or flashback-like experiences. The therapist must capture timing, context, emotional valence, and functional impact of these events.
1 role · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTRoute-of-administration awareness
The facilitator should understand the administration context for the intervention. The source highlights inhalation as the studied route and its rapid onset.
1 role · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaRoute-specific administration awareness
Facilitators need working knowledge of administration routes because onset, duration, intensity, and tolerability vary substantially. This informs preparation, monitoring, and participant education.
2 roles · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaSafety escalation and collaboration
Knows when to involve physicians, psychologists, and independent safety oversight. Complex psychedelic sessions require clear escalation pathways and team coordination.
1 role · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTSession-day eligibility and compliance checks
Clinicians must ensure participants meet day-of-session safety requirements before psilocybin is administered. This includes verifying toxicology, pregnancy, alcohol abstinence, and adherence to protocol restrictions.
2 roles · 1 guidelines · 0 courses · 0 providers
PsilocybinStructured smoking cessation treatment delivery
Facilitators must be able to deliver psilocybin only as an adjunct within a structured 15-week smoking cessation protocol rather than as a standalone intervention. This requires integrating psychedelic sessions with established tobacco cessation treatment methods.
1 role · 1 guidelines · 0 courses · 0 providers
PsilocybinStudy design integrity
Supports rigorous conduct of randomized controlled safety studies by maintaining protocol adherence and minimizing bias. Protects the validity of safety, tolerability, and exploratory efficacy assessments.
2 roles · 1 guidelines · 0 courses · 0 providers
IbogaineSubpsychedelic 5-MeO-DMT administration
Administers repeated sublingual microdoses of 5-MeO-DMT in a controlled clinical trial setting. Must follow the assigned dose schedule and maintain blinding across active and placebo conditions.
2 roles · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTDMT / AyahuascaSupervised at-home treatment oversight
Ability to support supervised at-home ketamine use when clinically appropriate. This implies monitoring and structure even outside the office setting.
1 role · 1 guidelines · 0 courses · 0 providers
KetamineUnderstand LSD dosing framework used in therapy
The intervention involved two dosing sessions with either low-dose or high-dose LSD, implying facilitators need knowledge of session-based LSD administration frameworks. This includes understanding that psychotherapy support is paired with specified dosing regimens.
1 role · 1 guidelines · 0 courses · 0 providers
LSDUnderstand psilocybin-assisted therapy as a rapid-acting intervention for depression
Facilitators require knowledge of the therapeutic context, including that psilocybin is being investigated as a rapid-acting treatment for major depressive disorder. This includes understanding the expected timeframe of symptom assessment and response.
1 role · 1 guidelines · 0 courses · 0 providers
PsilocybinUnderstanding of bipolar-specific risk context
The facilitator must understand why bipolar II participants require enhanced monitoring and conservative dosing. The protocol is built around the risk of mood destabilization in this population.
1 role · 1 guidelines · 0 courses · 0 providers
PsilocybinUnderstanding of dose-response limitations
Recognize that current evidence does not establish the lowest effective or safest exposure for ibogaine. Facilitators must understand the uncertainty surrounding efficacy at reduced doses.
1 role · 1 guidelines · 0 courses · 0 providers
IbogaineUse of cognitive and behavioral assessment domains
Understand the domains assessed in the Storyline psychiatric and neurological interviews and use this knowledge to support accurate administration and interpretation of study tasks. Domains include cognition, mood, homeostasis, social support, and psychosis/suicidality screening.
2 roles · 1 guidelines · 0 courses · 0 providers
KetamineUse of non-IV delivery model
Knowledge that KAP may be delivered without intravenous access and that non-IV office-based use is part of the described practice model. This reflects a shift from IV-only psychiatric use to broader administration approaches.
2 roles · 1 guidelines · 0 courses · 0 providers
KetamineUse self-directed enquiry
Help participants direct attention to their own present-moment internal experience and explore it from multiple perspectives. This is practiced in preparation and used to support participants if challenging material emerges during dosing.
2 roles · 1 guidelines · 0 courses · 0 providers
PsilocybinVital sign and clinical observation awareness
Understand the expected acute physiological effects of BPL-003 and monitor for clinically meaningful changes. The facilitator should recognize that transient blood pressure and heart rate increases may occur.
1 role · 1 guidelines · 0 courses · 0 providers
5-MeO-DMTCase-based practice, peer consultation, and professional learning community
Teaches applied competence through role play, case discussion, peer consultation, seminars, mentorship, and learning-community structures. The emphasis is translating theory into practice, receiving feedback, and developing reflective clinical judgment with peers.
7 roles · 0 guidelines · 8 courses · 7 providers
KetaminePsilocybinNeurobiology of non-ordinary states
Teaches the neurobiological basis of psychedelic and non-ordinary states, including default mode, salience, fear, and related brain-network models. The competency links altered-state phenomenology with therapeutic mechanisms and clinical implications.
4 roles · 0 guidelines · 4 courses · 4 providers
KetaminePsilocybinEthics and ethical practice
Cluster covering 4 related competencies including: Ethical practice, Ethics in psychedelic care, Ethics and ethical practice.
6 roles · 0 guidelines · 4 courses · 3 providers
MDMAPsilocybinClinical protocol literacy
Teaches practitioners to read and understand clinical protocols, treatment manuals, and evidence-based psychedelic care procedures. The focus is knowing how protocol requirements shape preparation, dosing, integration, documentation, and safety responsibilities.
6 roles · 0 guidelines · 2 courses · 2 providers
KetamineMDMAPsilocybinPreparation and therapeutic alliance
Cluster covering 2 related competencies including: Preparation and therapeutic alliance, Preparation and therapeutic alliance building.
3 roles · 0 guidelines · 2 courses · 2 providers
Dosing-session framework
Cluster covering 2 related competencies including: Dosing-session framework, Dosing-session framework use.
4 roles · 0 guidelines · 2 courses · 1 providers
MDMAPsilocybinPsilocybin prescribing fundamentals
Cluster covering 2 related competencies including: Psilocybin prescribing fundamentals, Prescribing fundamentals for psychedelic treatment.
2 roles · 0 guidelines · 2 courses · 1 providers
MDMAPsilocybinActive guiding and purposeful intervention
The course also teaches a more active guiding style, especially through Ralph Metzner’s approach, where guides may introduce focused inquiries, somatic practices, or other interventions. Learners are shown how interventions can shape the trajectory of a session when used skillfully.
3 roles · 0 guidelines · 1 courses · 1 providers
Apprenticeship and mentor shadowing
The program includes supervised apprenticeship hours with pre-approved mentors. Learners are expected to observe, assist, and translate training into supervised practice.
4 roles · 0 guidelines · 1 courses · 1 providers
PsilocybinClinical trial training and feedback use
The page highlights best-in-class clinical training for drug trials and AI-supported evaluation. Learners are expected to refine skills quickly and receive targeted feedback in training or evaluation contexts.
6 roles · 0 guidelines · 1 courses · 1 providers
Collaborative-care role awareness
The program emphasizes that it prepares people for therapeutic and facilitative roles within a collaborative care framework, not independent medical practice. Learners are expected to understand role boundaries, especially around prescribing and administration.
5 roles · 0 guidelines · 1 courses · 1 providers
KetaminePsilocybinCompound comparison for therapeutic use
The course teaches learners to distinguish between classic psychedelics and emerging therapies within therapeutic applications. This is a foundational comparative literacy competency rather than a protocol-specific skill.
6 roles · 0 guidelines · 1 courses · 1 providers
KetamineLSDMDMA+1 moreContemplative practice support
Contemplative practice is included as a core domain, suggesting learners are exposed to practices that support presence, reflection, and self-regulation in facilitation work. This likely supports both practitioner preparation and client-facing care.
3 roles · 0 guidelines · 1 courses · 1 providers
Expanded-state therapeutic skills
The course explicitly teaches techniques for working with patients in altered states, including grounding, breathwork, and mindfulness. These are presented as tools for supporting expanded and ordinary states of consciousness.
3 roles · 0 guidelines · 1 courses · 1 providers
KetamineHuman-centred, experiential facilitation
The overall program emphasizes experiential, relational, and community-grounded learning, including retreat and practicum components. Learners are expected to develop a grounded facilitation presence in addition to theory.
3 roles · 0 guidelines · 1 courses · 1 providers
MDMAPsilocybinMicrodosing and macrodosing protocol design
Learners are taught to design custom protocols for both microdosing and macrodosing based on client goals. The page also references microdosing formulas and practical application of timing and dosage nuances.
3 roles · 0 guidelines · 1 courses · 1 providers
PsilocybinObserving and holding space without reacting
Learners are expected to develop the ability to witness clients and processes calmly, without overreacting or trying to control the experience. The course explicitly frames this as foundational to practitioner development.
4 roles · 0 guidelines · 1 courses · 1 providers
Safety, ethics, and responsibility in expanded states work
The course explicitly states that facilitators are guided in safety, ethics, and responsibility. Learners are expected to recognize and manage the unique risks of working with altered states.
3 roles · 0 guidelines · 1 courses · 1 providers
PsilocybinStructured PAP process navigation
The course teaches the overall PAP workflow from screening through follow-up. Learners are expected to understand and explain each phase of treatment in a structured way.
4 roles · 0 guidelines · 1 courses · 1 providers
KetamineSupervised experiential practice
A defining feature of the training is hands-on experiential practice in both non-substance and substance-based modalities under supervision. Learners practice patient and therapist roles, facilitating and undergoing sessions in a structured learning context.
4 roles · 0 guidelines · 1 courses · 1 providers
PsilocybinSupervised practicum and feedback integration
Students complete 50 supervised practicum hours and receive expert feedback while working with real clients. This is intended to translate theory into competent applied practice.
4 roles · 0 guidelines · 1 courses · 1 providers
Supporting diverse spiritual and community contexts
The program states it prepares facilitators to address the needs of clients, patients, or community members from diverse faith traditions and communities of origin. Learners are expected to adapt facilitation to varied settings and worldviews.
3 roles · 0 guidelines · 1 courses · 1 providers
Tracking nervous systems and consent dynamics
The Colorado practicum site explicitly teaches relational competence, including tracking nervous systems, power, and consent dynamics moment by moment. This is presented as a core facilitation capability.
4 roles · 0 guidelines · 1 courses · 1 providers
PsilocybinHybrid in-person and virtual session support
The course teaches students to guide both in-person and online sessions, including the technical skills needed for virtual facilitation. It explicitly notes that online training includes learning tech skills to become a confident virtual guide.
3 roles · 0 guidelines · 0 courses · 1 providers
PsilocybinKetamineDMT / Ayahuasca+1 moreVirtual safety and support management
The program states that the virtual training has been streamlined so students feel safe and supported no matter what arises. This signals competency in maintaining safety in online psychedelic support contexts.
3 roles · 0 guidelines · 0 courses · 1 providers
General psychedelic-assisted practice skills
Catch-all cluster covering 189 general competencies for psychedelic-assisted clinical practice that did not group into a more specific category — including miscellaneous facilitation, monitoring, ethics, safety, regulatory awareness, group support, and program-specific skills not captured by dedicated clusters elsewhere.
8 roles · 45 guidelines · 27 courses · 18 providers
5-MeO-DMTDMT / AyahuascaIbogaine+5 more
Other care stages
Follow the competency map across the care pathway.